Novosom Licenses Next-Generation CD40 Targets From Isis
This article was originally published in The Pink Sheet Daily
Novosom plans to use Isis’ antisense oligonucleotides targeting CD40 with its proprietary Smarticles technology to enhance delivery.
You may also be interested in...
Firms confident, but some analysts skeptical about what might be required for approval of lipid antisense drug.
The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?
Orna is retaining full ownership of its "crown jewel," in situ CAR programs for cancer. CEO Tom Barnes talked to Scrip about the deal and Orna's business strategy.